Certification of a New Technology Demonstration Plan

Overview

The Ministry of Health, Labour and Welfare certified, on November 13, 2026, the application submitted by Fuji Electric Co., Ltd. to certify its New Technology Demonstration Plan, finding that it met each requirement under Article 8-2, Paragraph 4 of the Act on Strengthening Industrial Competitiveness. The plan will test the receipt of medicines in five categories, excluding medicines requiring guidance, by members of the public using a general medicine collection machine installed in part of an already-open pharmacy, under the proper supervision of pharmacists and others. The demonstration will begin within six months after preparations are complete and will run through the last day of the month containing the date one month after it begins.

This summary was automatically generated by AI. Please refer to the original article for accuracy.

Key points

  • On November 13, 2026, the Ministry of Health, Labour and Welfare certified the application submitted by Fuji Electric Co., Ltd. for its New Technology Demonstration Plan.
  • The plan will test the receipt of medicines in five categories, excluding medicines requiring guidance, by members of the public using a collection machine inside a pharmacy.
  • The demonstration will begin within six months after preparations are complete and will run through the last day of the month containing the date one month after it begins.

Overview

The Ministry of Health, Labour and Welfare decided to certify, on November 13, 2026, the application submitted by Fuji Electric Co., Ltd. for a New Technology Demonstration Plan under Article 8-2, Paragraph 1 of the Act on Strengthening Industrial Competitiveness (Act No. 98 of 2013), finding that it met all requirements under Paragraph 4 of that article. This is certification of a plan under the Act.

Details

The certified demonstration operator is Fuji Electric Co., Ltd. Its address is 1-11-2 Osaki, Shinagawa-ku, Tokyo, and its representative is Shiro Kondo, Representative Director, President and COO.

Under the plan, the demonstration will test whether medicines can be received by members of the public from a general medicine collection machine installed as part of an already-open pharmacy, under the proper supervision of pharmacists and others. The five categories covered are Category 1 medicines, designated medicines subject to abuse prevention, designated Category 2 medicines, Category 2 medicines, and Category 3 medicines; medicines requiring guidance are excluded.

The implementation period is set to begin within six months after certification, once preparations for the demonstration are complete, and continue through the last day of the month containing the date one month after the demonstration begins. The start deadline and end date are conditions for the implementation period specified in the plan.

Related Articles